Global healthcare major Abbott Laboratories has issued a nationwide alert to its distributors and stockists in India after fake batches of its popular antibiotic Amoxyclav 625 were found circulating in the market. The move comes amid growing concerns over the prevalence of counterfeit and substandard medicines in the Indian pharmaceutical supply chain.
Fake Batches Identified and Withdrawn
According to a communication accessed by us, Abbott’s pan-India franchise partner, Biomech Healthcare, circulated an urgent notice to all distributors, directing them to immediately stop the sale, purchase, or stocking of three specific batches of Amoxyclav 625 (10 tablets pack) — namely MFK0076, MKFO692, and MKF0722.
These batches, the communication said, have been “confirmed fake or counterfeit”, and distributors have been “strictly instructed not to procure, stock or sell them under any circumstances.”
The notice reads:
“We bring to your attention that Amoxyclav 625 10s batches MFK0076, MKFO692 and MKF0722 currently in circulation are confirmed fake or counterfeit. Please take necessary actions to protect public health and avoid any potential liability.”
Abbott’s official response to media queries on the issue is still awaited. However, the internal advisory highlights that the company is treating the matter with utmost seriousness and has taken the step as a precautionary measure to protect patient safety and product integrity.
What Is Amoxyclav 625?
Amoxyclav 625 is one of Abbott’s highest-selling antibiotic formulations in India, trusted by doctors and patients for decades. It is a combination of Amoxicillin and Clavulanic Acid, used to treat a wide range of bacterial infections — including pneumonia, ear and sinus infections, urinary tract infections, and skin and soft tissue infections.
Given its widespread use and brand reputation, the discovery of counterfeit versions poses a serious risk not just to patients, but also to the credibility of India’s pharmaceutical ecosystem.
Abbott’s Safety Measures and Distributor Instructions
The communication from Abbott and Biomech Healthcare urged all distribution partners to verify their stocks and ensure purchases are made only through authorised stockists.
“To ensure product authenticity and patient safety, please make all purchases exclusively through our authorised stockists,” the alert stated.
Stockists and distributors have also been directed to “immediately notify” Abbott or Biomech Healthcare if they come across any of the suspicious batches, and to cooperate fully in preventing further circulation of counterfeit stock.
The message further added that this advisory serves as a critical alert to safeguard the integrity of Abbott’s products and the well-being of patients, urging all partners for “prompt attention and responsible action.”
Rising Concern Over Counterfeit Drugs in India
This is not an isolated incident. India has been facing repeated cases of counterfeit and substandard drugs being detected in the market — particularly antibiotics, anti-malarials, and paediatric syrups.
In 2023 and early 2024, several global regulatory authorities, including the World Health Organization (WHO), raised alarms over Indian-manufactured cough syrups found to contain toxic contaminants in countries such as Gambia, Uzbekistan, and Cameroon.
According to WHO estimates, about 35% of fake drugs sold worldwide originate from India, reflecting the scale of the problem.
Experts say that while India is globally recognized as the “pharmacy of the world,” producing over 20% of the world’s generic medicines, it also faces challenges of weak enforcement, parallel supply chains, and inadequate verification systems in the domestic market.
The Economic and Ethical Impact
The presence of counterfeit medicines like fake Amoxyclav not only endangers patient lives but also undermines public trust in pharmaceutical brands and healthcare systems.
“Counterfeit antibiotics are especially dangerous because they may contain subtherapeutic doses or wrong ingredients,” said a senior pharmacologist on condition of anonymity. “This can lead to treatment failure and antimicrobial resistance — a silent pandemic already threatening global health.”
Moreover, counterfeit products eat into legitimate market share, causing financial losses for companies and tax revenue leakages for the government. The WHO estimates that counterfeit medicines cost the global economy over $30 billion annually.
Need for Stronger Regulation and Digital Verification
The incident has reignited discussions around the urgent need for robust track-and-trace mechanisms in India’s drug supply chain. The government has been pushing for implementation of barcoding and digital traceability under the Drug Authentication and Verification Application (DAVA) system and new QR code mandates by the Central Drugs Standard Control Organisation (CDSCO).
Once fully operational, such systems could help pharmacists and consumers instantly verify the authenticity of medicines using a mobile app or QR code scan.
However, experts argue that the system’s success will depend on widespread compliance by manufacturers, wholesalers, and retailers, as well as consumer awareness.
A Call for Vigilance
Abbott’s latest action serves as a reminder that even the most reputed multinational companies are not immune to counterfeiting threats in India’s vast and complex pharmaceutical landscape.
Healthcare professionals are being urged to check packaging carefully, verify batch numbers, and report any suspicious product variations — such as differences in colour, texture, or print quality — to the authorities.
Meanwhile, patients should purchase medicines only from licensed pharmacies, avoid online sellers without verified credentials, and check for manufacturing and expiry details on every strip.
Conclusion
The detection of counterfeit Amoxyclav 625 highlights the growing need for joint accountability between pharma companies, regulators, and the healthcare supply chain. Abbott’s swift action and transparent communication reflect an encouraging step toward patient safety.
But experts say the problem runs deeper — requiring systemic reforms, technology-driven traceability, and strict enforcement to ensure that the medicines reaching Indian households are 100% genuine.
Until then, the call for vigilance continues — for companies, chemists, and consumers alike.
